Key Concerns ⁤in the 2023 ‌Prescrire Review

The latest review ⁤by⁣ Prescrire, a⁢ French independent ‌medical journal, identifies several recently approved medications ⁤with perhaps serious risks. The journal emphasizes⁤ that drug availability doesn’t automatically equate to therapeutic benefit and ⁤aims to provide a critical,independent risk assessment for healthcare providers.

Several medications are highlighted for ‍specific ​adverse effects:

• Romboembolic Accidents: The review notes an increased risk of romboembolic accidents compared ‌to​ usual⁢ care.
• Chondroitin: While⁤ commonly prescribed for osteoarthritis, chondroitin can trigger hypersensitivity⁢ reactions in some patients.
• Fezolintant: This drug, indicated for hot ⁤flashes associated with menopause, carries a significant risk of hepatotoxicity ⁣(liver damage) and‌ can cause digestive ‍or neuropsychic disorders.
• Gefapixant: Used to treat refractory⁤ chronic cough in the ‌ European Union, gefapixant is ​associated with very frequent taste disorders, as well as potential​ risks of pneumonia and ‍urinary‍ problems.

Understanding the Prescrire Methodology

Prescrire‘s annual review ⁤is‍ based on a rigorous⁣ evaluation of clinical​ trial data, post-market surveillance reports, and published literature. The ⁢journal’s editorial team, comprised of physicians and pharmacists, independently assesses​ the benefit-risk balance of‍ medications. Unlike many drug evaluations funded by pharmaceutical companies,Prescrire receives no‍ funding from the pharmaceutical industry,ensuring⁤ its ⁤objectivity. The journal’s⁢ website states its objective is to “provide ⁤an independent risk assessment to guide safer and better-informed care choices.”

the review ⁢isn’t simply a list of “bad” drugs. It‌ highlights situations where‌ the risks outweigh the benefits, or where safer alternatives⁢ exist. It also points ‌out drugs where ⁤the evidence of efficacy⁢ is weak or lacking.

Implications for Patients and⁣ Healthcare ​Providers

This review serves as a‌ crucial ⁢reminder for both patients and healthcare providers to ⁣engage⁢ in⁢ shared decision-making. Patients should discuss the potential risks and benefits of any medication⁢ with their ⁢doctor,and explore option treatment options when ‌appropriate.Healthcare providers should carefully ‌consider the prescrire ⁢ findings alongside other clinical⁤ facts when prescribing medications.

The focus on hepatotoxicity⁣ with Fezolintant,such as,underscores the importance of⁤ liver function monitoring in patients taking this ⁢medication. Similarly, the frequent taste disturbances associated with ⁤Gefapixant could significantly impact​ a patient’s quality of life, prompting a discussion ‌about ‍whether the ‌benefits outweigh‍ this side ⁣effect.

A Deeper ⁤Look at Gefapixant and Chronic Cough

Gefapixant, a⁣ selective NK1 receptor antagonist, ⁣was⁤ approved in the European union for the treatment of chronic cough that persists for more than eight weeks without an identifiable cause. ‌While offering a potential​ solution for a debilitating condition, its side effect ⁢profile warrants ​careful consideration. The reported‌ incidence of taste disorders is​ particularly high,